Laparoscopy Assisted versus Open Distal Gastrectomy with D2 Lymph Node Dissection for Advanced Gastric Cancer: Design and Rationale of a Phase II Randomized Controlled Multicenter Trial (COACT 1001).
10.5230/jgc.2013.13.3.164
- Author:
Byung Ho NAM
1
;
Young Woo KIM
;
Daniel REIM
;
Bang Wool EOM
;
Wan Sik YU
;
Young Kyu PARK
;
Keun Won RYU
;
Young Joon LEE
;
Hong Man YOON
;
Jun Ho LEE
;
Oh JEONG
;
Sang Ho JEONG
;
Sang Eok LEE
;
Sang Ho LEE
;
Ki Young YOON
;
Kyung Won SEO
;
Ho Young CHUNG
;
Oh Kyoung KWON
;
Tae Bong KIM
;
Woon Ki LEE
;
Seong Heum PARK
;
Ji Young SUL
;
Dae Hyun YANG
;
Jong Seok LEE
Author Information
1. Gastric Cancer Branch, Research Institute & Hospital, National Cancer Center, Goyang, Korea. gskim@ncc.re.kr
- Publication Type:Multicenter Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Gastrectomy;
Stomach neoplasms;
Lymph node excision
- MeSH:
Arm;
Disease-Free Survival;
Endoscopy;
Gastrectomy;
Humans;
Informed Consent;
Laparoscopy;
Length of Stay;
Lymph Node Excision;
Lymph Nodes;
Postoperative Complications;
Prospective Studies;
Sample Size;
Stomach Neoplasms
- From:Journal of Gastric Cancer
2013;13(3):164-171
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Laparoscopy-assisted distal gastrectomy for early gastric cancer has gained acceptance and popularity worldwide. However, laparoscopy-assisted distal gastrectomy for advanced gastric cancer is still controversial. Therefore, we propose this prospective randomized controlled multi-center trial in order to evaluate the safety and feasibility of laparoscopy assisted D2-gastrectomy for advanced stage gastric cancer. MATERIALS AND METHODS: Patients undergoing distal gastrectomy for advanced gastric cancer staged cT2/3/4 cN0/1/2/3a cM0 by endoscopy and computed tomography are eligible for enrollment after giving their informed consent. Patients will be randomized either to laparoscopy-assisted distal gastrectomy or open distal gastrectomy. Sample size calculation revealed that 102 patients are to be included per treatment arm. The primary endpoint is the non-compliance rate of D2 dissection; relevant secondary endpoints are three-year disease free survival, surgical and postoperative complications, hospital stay and unanimity rate of D2 dissection evaluated by reviewing the intraoperative video documentation. DISCUSSION: Oncologic safety is the major concern regarding laparoscopy-assisted distal gastrectomy for advanced gastric cancer. Therefore, the non-compliance rate of clearing the N2 area was chosen as the most important parameter for the technical feasibility of the laparoscopic procedure. Furthermore, surgical quality will be carefully reviewed, that is, three independent experts will review the video records and score with a check list. For a long-term result, disease free survival is considered a secondary endpoint for this trial. This study will offer promising evidence of the feasibility and safety of Laparoscopy-assisted distal gastrectomy for advanced gastric cancer.Trial Registration: NCT01088204 (international), NCCCTS-09-448 (Korea).
